Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
• •* Stage III or IV disease
• •The following histologic epithelial cell types are allowed:
• •* Serous adenocarcinoma
• •* Mucinous adenocarcinoma
• •* Clear cell adenocarcinoma
• •* Endometrioid adenocarcinoma
• •* Mixed epithelial carcinoma
• •* Undifferentiated carcinoma
• •* Transitional cell carcinoma
• •* Malignant Brenner tumor
• •* Adenocarcinoma not otherwise specified
• •Must have undergone appropriate surgery for ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer within the past 6 weeks
• •No borderline ovarian tumor of low malignant potential
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •GOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Hemoglobin ≥ 8.0 g/dL
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •Meets 1 of the following criteria:
• •* Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
• •* AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• •* AP ≤ 5 times ULN AND AST or ALT normal
• •No hepatic disease that would preclude study participation
• •Renal
• •Creatinine ≤ 2.0 mg/dL
• •Creatinine clearance \> 50 mL/min
• •No renal disease that would preclude study participation
• •Cardiovascular
• •LVEF ≥ lower limit of normal\*
• •No poorly controlled arrhythmia
• •No unstable coronary artery disease
• •No myocardial infarction within the past year NOTE: \*LVEF evaluation performed only on patients requiring it
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• •No peripheral neuropathy ≥ grade 2
• •No other nonmalignant systemic disease that would preclude study participation
• •No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
• •No medical, social, or psychosocial factor that would preclude study participation
• •No psychiatric or addictive disorder that would preclude giving informed consent
• •No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix or breast
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior immunotherapy for this malignancy
• •Chemotherapy
• •No prior chemotherapy for this malignancy
• •Endocrine therapy
• •No prior hormonal therapy for this malignancy
• •Radiotherapy
• •No prior radiotherapy for this malignancy
• •Surgery
• •See Disease Characteristics
• •No planned interval cytoreductive surgery
• •* Second-look surgery allowed
• •Other
• •More than 1 year since prior experimental or investigational therapy
• •No concurrent therapeutic anticoagulation with warfarin